GlassScriptPhysician profile
Richard C Feldstein
NPI 1851533699
$20,467.09
in general payments reported to CMS, 2019-2025
39 companies · $4,444 in 2025
The $4,444 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,998 · 2020: $1,156 · 2021: $2,445 · 2022: $3,350 · 2023: $3,537 · 2024: $3,537 · 2025: $4,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,504.42 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,375.87 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Abbvie INC. | $2,891.40 | 2019-2025 | |
| Qol Medical, LLC | $1,739.83 | 2019-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $1,460.44 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,101.99 | 2019-2025 | Entyvio, Eohilia |
| Braintree Laboratories, INC. | $884.99 | 2019-2025 | Sutab, Suflave |
| Celgene Corporation | $803.21 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $778.38 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $768.53 | 2019-2023 | Rebyota |
| Pfizer INC. | $688.22 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $629.54 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $404.74 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $372.15 | 2022-2025 | Stelara, Simponi Aria, Simponi |
| Ardelyx, INC. | $365.12 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $314.95 | 2024-2025 | Voquezna |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $248.02 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Intercept Pharmaceuticals, INC. | $214.96 | 2019-2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $206.29 | 2019-2024 | Dificid |
| Genzyme Corporation | $184.23 | 2023-2025 | |
| Daiichi Sankyo INC. | $159.01 | 2019-2023 | Injectafer |
| Boston Scientific Corporation | $155.94 | 2025 | Axios |
| Ucb, INC. | $87.50 | 2019-2020 | |
| Vivus LLC | $78.13 | 2022-2025 | Qsymia |
| Aimmune Therapeutics, INC. | $65.02 | 2024-2025 | Zenpep |
| Allergan, INC. | $64.28 | 2019 | |
| Evoke Pharma, INC. | $61.60 | 2024-2025 | |
| Exact Sciences Corporation | $57.56 | 2025 | Cologuard Collection Kit |
| Ipsen Biopharmaceuticals, INC | $55.02 | 2025 | Iqirvo |
| Alfasigma USA, INC. | $52.48 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $29.30 | 2025 | Wainua |
| Lilly USA, LLC | $25.77 | 2025 | Omvoh |
| Novo Nordisk INC | $25.49 | 2025 | Wegovy |
| Sanofi US Services INC. | $23.35 | 2024 | |
| Echosens North America, INC. | $22.00 | 2023 | Fibroscan |
| Shire North American Group INC | $16.03 | 2019 | |
| Gilead Sciences, INC. | $15.70 | 2019 | |
| Capsovision, INC. | $15.39 | 2023 | Capsocam Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.87 | 2023 | Cyltezo |
| Ethicon US, LLC | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Feldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.